Similar effects of ORR were reported with Nivolumab (HPV-positive vs. HPV-negative, 15.9% vs. 8.0%) [5] and annti-PD-L1 agent Durvalumab (HPV-positive vs. HPV-negative, 30% vs. 10.8%) [32] in recurrent or metastatic HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.